NASDAQ:IONS Ionis Pharmaceuticals Q3 2026 Earnings Date & Estimates $45.28 +1.98 (+4.57%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$45.08 -0.20 (-0.44%) As of 10/9/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Ionis Pharmaceuticals is expected to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for October 28, 2026 at 11:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 4, 2026TimeBefore Market OpensConference Call DateOctober 28, 2026Conference Call11:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Ionis Pharmaceuticals in Q3 2026Ionis Pharmaceuticals is expected to post earnings of -$1.21 per share on revenue of $183.13 million. In the same quarter a year earlier Ionis Pharmaceuticals reported -$0.80 per share on revenue of $156.72 million. Ionis Pharmaceuticals last reported on April 29, 2026, posting -$0.56 per share and beating the -$0.85 consensus estimate. Ionis Pharmaceuticals has beaten the consensus EPS estimate in 7 of its last 8 quarters.Consensus EstimatesConsensus EPS-$1.21Expected Revenue$183.13 millionPrior-Year EPS-$0.80Prior-Year Revenue$156.72 millionExpected Revenue Growth+16.9%Recent Track RecordLast ReportedQ1 2026Last Quarter EPS-$0.56 (Beat by +$0.29)Last Quarter Revenue$246.09 millionEPS Beat Rate7 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ1 2026 Earnings ReportQ4 2025 Earnings ReportQ3 2025 Earnings Report Ionis Pharmaceuticals Q3 2026 Earnings FAQ When does Ionis Pharmaceuticals report Q3 2026 earnings? Ionis Pharmaceuticals (NASDAQ:IONS) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Ionis Pharmaceuticals' Q3 2026 earnings call? Ionis Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Wednesday, October 28, 2026 at 11:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Ionis Pharmaceuticals? Analysts expect Ionis Pharmaceuticals to post earnings of -$1.21 per share for Q3 2026. How much revenue is Ionis Pharmaceuticals expected to report? The consensus revenue estimate for Ionis Pharmaceuticals is $183.13 million for Q3 2026. Ionis Pharmaceuticals Earnings HeadlinesIonis Pharmaceuticals (IONS) Receives a Buy from Bank of America Securities3 hours ago | theglobeandmail.comAlnylam vs. Ionis: Here's the Better Bad-News BuyOctober 10 at 4:44 AM | fool.comHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.October 10 at 1:00 AM | Banyan Hill Publishing (Ad)Ionis Pharmaceuticals (IONS) After The Pullback Is The Undervalued Narrative Still IntactOctober 9 at 8:34 PM | finance.yahoo.comIonis Pharmaceuticals (IONS) Stock Could Still Trade At A Premium Despite A 46% SlumpOctober 8 at 11:41 PM | uk.finance.yahoo.comIonis Pharmaceuticals (NASDAQ:IONS) Sets New 1-Year Low - Time to Sell?October 5, 2026 | americanbankingnews.comSee More Ionis Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ionis Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ionis Pharmaceuticals and other key companies, straight to your email. Email Address About Ionis PharmaceuticalsIonis Pharmaceuticals (NASDAQ:IONS) is a biotechnology company focused on discovering and developing RNA-targeted medicines. The company’s antisense technology is designed to selectively bind to RNA and modify the production of disease-associated proteins. Its research programs address neurological, cardiovascular, metabolic and other serious diseases. Ionis has developed medicines both independently and through collaborations with larger pharmaceutical companies. Its products and partnered therapies have included treatments for spinal muscular atrophy, hereditary transthyretin-mediated amyloidosis, familial chylomicronemia syndrome and transthyretin amyloidosis with cardiomyopathy or polyneuropathy. The company also maintains a pipeline of investigational antisense medicines targeting conditions with significant unmet medical needs. Founded in 1989 as Isis Pharmaceuticals, the company adopted the name Ionis Pharmaceuticals in 2015. Based in Carlsbad, California, Ionis serves international markets through its own commercial activities and strategic partnerships. Brett P. Monia serves as chief executive officer.View Ionis Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
